Medicine
Relenza 5 mg inhalation powder
Relenza 5 mg inhalation powder is a prescription medicine containing Zanamivir for inhalation use, marketed by GlaxoSmithKline, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store at 25 ° C (77 ° F), excursions permitted to 15 ° to 30 ° C (59 ° to 86 °…
Key facts
- Active ingredient (INN)
- Zanamivir
- Brand
- Relenza
- Strength
- 5 mg
- Dosage form
- Inhalation powder
- Route
- Inhalation
- Packs
- 5 package
- Marketing authorisation holder
- GlaxoSmithKline
- Manufacturers
- GlaxoSmithKlineA-S Medication Solutions
- Origin register
- US FDA, United States
- Storage
- Store at 25 ° C (77 ° F), excursions permitted to 15 ° to 30 ° C (59 ° to 86 ° F).
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- J05AH01 Zanamivir
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 22 September 1999
- Identifiers
- RxCUI 759471, 759473DailyMed set ID d7c3bcc3-0c0d-4068-fd80-88cf54a376ef, b4e68930-4e6d-4d27-b1f0-abf60d12e28dNDC 0173-0681, 50090-8016Application NDA021036
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 5 package in 1 carton / 4 powder in 1 package | 0173-0681-01 | GlaxoSmithKline | 22 September 1999 |
| 5 package in 1 carton / 4 powder in 1 package | 0173-0681-22 | GlaxoSmithKline | 9 March 2007 |
| 5 package in 1 carton / 4 powder in 1 package | 50090-8016-0 | A-S Medication Solutions | 16 July 2026 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Clinical summary
Zanamivir is a neuraminidase inhibitor indicated for treatment of acute, uncomplicated influenza type A and B infections in patients aged 7 years and older who have been symptomatic for no more than 2 days. MedsAcross supplies Zanamivir for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about ZanamivirFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- RELENZA prescribing information (GlaxoSmithKline) · U.S. National Library of Medicine, DailyMed
- Dectova: European public assessment report (EPAR) · European Medicines Agency
Need Relenza 5 mg inhalation powder for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.